Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2019 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Management to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

CAMBRIDGE, Mass., April 24, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
April 01, 2019 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Announces Appointment of Wendy Dwyer as Chief Business Officer

CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
March 07, 2019 16:01 ET | Source: Surface Oncology, Inc.

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2018

CAMBRIDGE, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
March 04, 2019 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology to Present at the 39th Annual Cowen Healthcare Conference

CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
February 04, 2019 16:21 ET | Source: Surface Oncology, Inc.

Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388

IL-27 is a key regulator of checkpoint protein expressionSRF388 believed to be the only anti-IL-27 targeted agent in late-preclinical developmentInvestigational New Drug (IND) submission for SRF388...
January 16, 2019 16:50 ET | Source: Surface Oncology, Inc.

Publication in ImmunoHorizons Highlights the Role of IL-27 in Upregulation of Multiple Checkpoint Proteins

- Expression of IL-27 shown to contribute to upregulation of PD-L1, LAG-3, CTLA-4, and TIGIT - Surface Oncology will submit an IND for SRF388, a first-in-class IL-27 antibody, in Q4 2019 CAMBRIDGE,...
January 04, 2019 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Announces Appointment of F. Stephen Hodi, MD to its Scientific Advisory Board

CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
December 21, 2018 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Added to the NASDAQ Biotechnology Index

CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
December 18, 2018 16:01 ET | Source: Surface Oncology, Inc.

Surface Oncology Resets Portfolio Priorities, Extends Cash Runway Through 2021

Significantly reduces scope of its CD47 program, SRF231Accelerates IND filing for SRF388 (IL-27) into Q4 2019IND filing for SRF617 (CD39) remains on track for Q4 2019 CAMBRIDGE, Mass., Dec. 18,...
December 17, 2018 07:00 ET | Source: Surface Oncology, Inc.

Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations

CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...